Dr. Chellapandian specializes in bone marrow transplant as a hematologist/oncologist and serves as Director of the Center for Cell and Gene Therapy for Non-Malignant Conditions (CCGNC) in the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. He joined the hospital staff in 2017. In 2022, he became interim division chief of the bone marrow transplant program.
Dr. Chellapandian earned his medical degree from Madurai Medical College and then trained at Postgraduate Institute of Medical Education and Research, both in India. He completed a residency in pediatrics at Albert Einstein Medical Center in Philadelphia, Pennsylvania. Dr. Chellapandian completed a pediatric hematology-oncology and bone marrow transplantation fellowship at Hospital for Sick Children/University of Toronto in Canada and an advanced fellowship on bone marrow transplantation and cellular therapy at St. Jude Children’s Research Hospital in Memphis, Tennessee.
Dr. Chellapandian's clinical and research interests include hematopoietic stem cell transplant for primary immunodeficiency, immune dysregulation disorders, sickle cell disease, thalassemia, and treatment of histiocytic disorders. He has special focus on ex-vivo graft engineering techniques and autologous gene therapy. He has adapted new methods of T- cell depletion using haploidentical transplantation to transplant patients lacking a suitable matched donor. He has numerous scientific papers and review articles published in this field.